CLYM
Climb Bio Inc
NASDAQ: CLYM · HEALTHCARE · BIOTECHNOLOGY
$8.88
+1.14% today
Updated 2026-04-30
Market cap
$436.60M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-0.88
Dividend yield
—
52W range
$1 – $10
Volume
0.6M
WallStSmart proprietary scores
28
out of 100
Grade: F
Strong Sell
Investment rating
4.3
Growth
C5.0
Quality
C+3.0
Profitability
D5.0
Valuation
C+—/9
Piotroski F-Score
—
—
Altman Z-Score
—
—
Industry rank
—
View all highly rated stocks (75+) →206 stocks currently score above 75
Price targets
Analyst target
$16.25
+83.00%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
1 Strong Buy11 Buy0 Hold0 Sell0 Strong Sell
Price chart
X-Ray snapshot
Strengths
Insufficient data
Risks
- Thin margins at 0.00%
- Negative free cash flow $-15.63M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | $-45.24M | $-35.12M | $-73.90M | $-59.85M | $-17.52M |
| EPS | — | — | — | — | $-0.88 |
| Free cash flow | $-37.37M | $-20.60M | $-15.56M | $-54.54M | $-15.63M |
| Profit margin | — | — | — | — | — |
Peer comparison
Smart narrative
Climb Bio Inc trades at $8.88. Our Smart Value Score of 28/100 indicates the stock is weak.
Frequently asked questions
What is Climb Bio Inc's stock price?
Climb Bio Inc (CLYM) trades at $8.88.
Is Climb Bio Inc overvalued?
Smart Value Score 28/100 (Grade F, Strong Sell).
What is the price target of Climb Bio Inc (CLYM)?
The analyst target price is $16.25, representing +83.0% upside from the current price of $8.88.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio—
ROE-32.20%
Beta-0.20
50D MA$7.24
200D MA$3.79
Shares out0.05B
Float0.03B
Short ratio—
Avg volume0.6M
Performance
1 week+1.39%
1 month+35.33%
3 months+85.55%
YTD+137.50%
1 year—
3 years—
5 years—